"Immunotherapy, Adoptive" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)
MeSH Number(s)
E02.095.465.425.400.330.050.400
E05.478.550.520.050.400
Concept/Terms
Immunotherapy, Adoptive- Immunotherapy, Adoptive
- Immunotherapy, Adoptive Cellular
- Adoptive Immunotherapy
- Adoptive Immunotherapies
- Immunotherapies, Adoptive
- Cellular Immunotherapy, Adoptive
- Adoptive Cellular Immunotherapies
- Cellular Immunotherapies, Adoptive
- Immunotherapies, Adoptive Cellular
- Adoptive Cellular Immunotherapy
Below are MeSH descriptors whose meaning is more general than "Immunotherapy, Adoptive".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy, Adoptive".
This graph shows the total number of publications written about "Immunotherapy, Adoptive" by people in Harvard Catalyst Profiles by year, and whether "Immunotherapy, Adoptive" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 6 | 5 | 11 |
1995 | 4 | 4 | 8 |
1996 | 4 | 6 | 10 |
1997 | 2 | 3 | 5 |
1998 | 3 | 2 | 5 |
1999 | 2 | 5 | 7 |
2000 | 1 | 1 | 2 |
2001 | 1 | 0 | 1 |
2002 | 3 | 3 | 6 |
2003 | 3 | 6 | 9 |
2004 | 4 | 0 | 4 |
2005 | 4 | 2 | 6 |
2006 | 2 | 4 | 6 |
2007 | 5 | 1 | 6 |
2008 | 6 | 5 | 11 |
2009 | 2 | 3 | 5 |
2010 | 2 | 3 | 5 |
2011 | 10 | 0 | 10 |
2012 | 3 | 8 | 11 |
2013 | 6 | 4 | 10 |
2014 | 8 | 6 | 14 |
2015 | 10 | 5 | 15 |
2016 | 10 | 5 | 15 |
2017 | 19 | 7 | 26 |
2018 | 39 | 11 | 50 |
2019 | 43 | 11 | 54 |
2020 | 48 | 21 | 69 |
2021 | 49 | 27 | 76 |
2022 | 16 | 55 | 71 |
2023 | 14 | 67 | 81 |
2024 | 2 | 12 | 14 |
Below are the most recent publications written about "Immunotherapy, Adoptive" by people in Profiles.
-
Understanding Mechanisms of Response to CAR T-cell Therapy through Single-Cell Sequencing: Insights and Challenges. Blood Cancer Discov. 2024 Mar 01; 5(2):86-89.
-
Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment. Haematologica. 2024 Mar 01; 109(3):777-786.
-
Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy. J Immunother Cancer. 2024 Feb 29; 12(2).
-
Stem cells in disguise. Science. 2024 Feb 16; 383(6684):714.
-
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood. 2024 Feb 08; 143(6):496-506.
-
A dual-receptor T-cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML. Blood. 2024 Feb 08; 143(6):507-521.
-
Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Blood. 2024 Feb 01; 143(5):404-416.
-
Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat Med. 2024 Feb; 30(2):338-341.
-
CAR Immunotherapy for the treatment of infectious diseases: a systematic review. Front Immunol. 2024; 15:1289303.
-
Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma. Blood Adv. 2024 01 23; 8(2):484-496.